Besponsa (Inotuzumab Ozogamicin) Trial Overview & amp; Conclusions - Hagop M. Kantarjian, MD
Hagop M. Kantarjian, MD of MD Anderson Cancer Center's Department of Leukemia gives the trial overview and conclusions of Pfizer's newly approved FDA CD22-directed antibody-drug conjugate Besponsa (In...
Author: Cancer-News
Added: 08/29/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts